Sulfur Containing Patents (Class 424/117)
-
Patent number: 8609083Abstract: This invention relates to using bacterial metabolites to suppress phytopathogens, more particularly this invention relates to bacterial metabolites applied to Carya illinoensis and Prunus persica as a fungicide to suppress and inhibit Glomerella cingulata, Phomopsis sp., Phytophthora cactorum, Fusicladosporium effusum, and Monilinia fructicola.Type: GrantFiled: March 22, 2007Date of Patent: December 17, 2013Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: David I. Shapiro-Ilan, Charles C. Reilly
-
Patent number: 7851439Abstract: Organic compounds that are useful for the treatment, prevention and/or amelioration of diseases are described.Type: GrantFiled: May 30, 2007Date of Patent: December 14, 2010Assignee: Novartis AGInventors: Simon Bushell, Matthew LaMarche, Michael J. Patane, Lewis Whitehead
-
Patent number: 6844182Abstract: This invention is directed to Bacillus mutants which produce a factor which potentiates the pesticidal activity of a Bacillus related pesticide, a chemical pesticide and/or a virus with pesticidal properties.Type: GrantFiled: May 15, 2001Date of Patent: January 18, 2005Assignee: Valent BioSciences CorporationInventors: Helle Outtrup, William D. Lidster, Susan C. MacIntosh, Robert L. Starnes, Denise Carol Manker
-
Publication number: 20030202957Abstract: The field of colonic diagnostic and surgical procedures is hampered by the lack of optimal means available to cleanse the colon. A compromise between convenient, distasteful, solid or low volume, hyperosmotic solutions which cause considerable fluid and electrolyte imbalances in patients and large volume, difficult to consume, iso-osmotic solutions has had to be made heretofore. This invention describes a low volume, hyperosmotic solution consisting of sulfate salts with and with out polyethylene glycol. Unlike prior art, this composition is useful for the cleansing of the bowel and, in lower volumes, as a laxative, without producing clinically significant changes in bodily function.Type: ApplicationFiled: April 30, 2002Publication date: October 30, 2003Inventor: Mark vB. Cleveland
-
Patent number: 6224864Abstract: Antibiotic 10381a1, wherein R is hydrogen, is a cytosine-containing antibiotic producible by culturing the novel microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. Derivatives wherein R is a C1 to C3 alkyl ester of antibiotic 10381a1, are also disclosed along with the pharmaceutically acceptable salts of both the native and esterified forms. Antibiotic 10381a1 inhibits the growth of selected species of yeast, fungi and bacteria. This invention also relates to a novel process for the preparation of the antibiotics 10381b and to a method of using antibiotics 10381b to promote growth in meat-producing animals. These antibiotics are also obtained by the fermentation of a nutrient medium with the novel microorganism Streptomyces arginensis and are active against selected species of bacteria.Type: GrantFiled: August 10, 1999Date of Patent: May 1, 2001Assignee: Pharmacia & Upjohn CompanyInventors: Alexander D. Argoudelis, Franklin B. Shilliday, Alice L. Laborde, Scott E. Truesdell, Oldrich K. Sebek
-
Patent number: 6214340Abstract: This invention provides a physiologically active substance having a strong dipeptidyl peptidase IV inhibitory activity. The physiologically active substance sulphostin is obtained by culturing a microorganism belonging to the genus Streptomyces and having an ability to produce the physiologically active substance sulphostin, producing and accumulating this substance in the cultures, and harvesting it from the cultures.Type: GrantFiled: May 12, 2000Date of Patent: April 10, 2001Assignee: Zaidan Hojin Biseibutsu Kagaku Kenkyu KaiInventors: Tomio Takeuchi, Masa Hamada, Yasuhiko Muraoka, Tetsuo Akiyama, Masatoshi Abe, Hiroshi Naganawa, Yoshikazu Takahashi
-
Patent number: 6159443Abstract: A method of delivering an active agent to a target tissue, particularly neoplastic tissue, vascular anomaly or tumor tissue, in a vertebrate subject. The method includes the steps of exposing the target tissue to ionizing radiation; and administering a delivery vehicle to the vertebrate subject before, after, during, or combinations thereof, exposing the target tissue to the ionizing radiation. The delivery vehicle includes the active agent and delivers the agent to the target tissue. Exemplary delivery vehicles include platelets; leukocytes; proteins or peptides which bind activated platelets; antibodies which bind activated platelets; microspheres coated with proteins or peptides which bind activated platelets; liposomes conjugated to platelets, leukocytes, proteins or peptides which bind activated platelets, or antibodies which bind activated platelets; and combinations thereof.Type: GrantFiled: April 29, 1999Date of Patent: December 12, 2000Assignee: Vanderbilt UniversityInventor: Dennis E. Hallahan
-
Patent number: 6106836Abstract: The present invention relates to a vaccine container that contains one or more freeze-dried vaccine components. The vaccine component or components are present in two or more freeze-dried bodies, at least one of which is a lyosphere.Furthermore, the invention relates to methods for the preparation of such a vaccine container.Also, the invention relates to a vaccine pack, comprising the vaccine container.Type: GrantFiled: February 17, 1999Date of Patent: August 22, 2000Assignee: Akzo Nobel N.V.Inventors: Antonius Theodorus Maria Wilderbeek, Hans Almer Middelbeek
-
Patent number: 6093381Abstract: Disclosed is a method for improving the treatment of a cancer patient which is undergoing (adjuvant) chemotherapy. Prior to or concomitant with the patient receiving adjuvant chemotherapy, the patient is administered mitogenically stimulated lymph node lymphocytes or the supernatant therefrom. The lymph node lymphocytes are patient excised lymph node lymphocytes enriched in tumor reactive cells, such as CD4+ tumor reactive cells. Radiolabeled locators (e.g., antibodies) can be used along with a portable radiation detector to intraoperatively determine which lymph nodes bear lymph node lymphocytes enriched in tumor reactive cells. The patient excised lymph node lymphocytes enriched in tumor reactive cells then are subjected to mitogenic stimulation for their expansion and administration to the patient.Type: GrantFiled: December 10, 1997Date of Patent: July 25, 2000Assignee: Neoprobe CorporationInventors: Pierre L. Triozzi, Julian A. Kim
-
Patent number: 5997846Abstract: The present invention provides a method for detecting chitin-containing organisms on an area of a person or animal by contacting the particular area with a dye that is capable of biding to chitin and emitting fluorescence upon exposure to light. If a chitin-containing organism is present in the treated area, the chitin of the organism will bind the dye and, upon exposure to light, the chitin-containing organisms may be visualized and removed. Also provided by the present invention are solutions and suspensions that contain a dye capable of binding to a chitin-containing organism and emitting florescence upon exposure to light. The solutions and suspensions provided herein may be in the form of a shampoo, cream, lotion or detergent for the detection of chitin-containing organisms present in body hair, on the skin, clothing or the fur of animals. The solutions and suspensions may also be in a form suitable for spraying on clothes, as well as on the hair, skin and fur.Type: GrantFiled: November 17, 1997Date of Patent: December 7, 1999Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Edward R. Burns, Murray Wittner, Fagie Faskowitz
-
Patent number: 5985274Abstract: Antibiotic 10381a.sub.1, wherein R is hydrogen, is a cytosine-containing antibiotic producible by culturing the novel microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. Derivatives wherein R is a C.sub.1 to C.sub.3 alkyl ester of antibiotic 10381a.sub.1, are also disclosed along with the pharmaceutically acceptable salts of both the native and esterified forms. Antibiotic 10381a.sub.1 inhibits the growth of selected species of yeast, fungi and bacteria. This invention also relates to a novel process for the preparation of the antibiotics 10381b and to a method of using antibiotics 10381b to promote growth in meat-producing animals. These antibiotics are also obtained by the fermentation of a nutrient medium with the novel microorganism Streptomyces arginensis and are active against selected species of bacteria.Type: GrantFiled: June 5, 1995Date of Patent: November 16, 1999Assignee: Pharmacia & Upjohn CompanyInventors: Alexander D. Argoudelis, deceased, Franklin B. Shilliday, Alice L. Laborde, Scott E. Truesdell, Oldrich K. Sebek
-
Patent number: 5985281Abstract: A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprising a prodrug convertible under the influence of the mutated enzyme to the antineoplastic drug. The mutated enzyme is a mutated form of a natural host enzyme which recognizes its natural substrate by an ion pair interaction with the substrate, wherein the mutated enzyme and prodrug have structures such that the polarity of the mutated enzyme/prodrug ion pair interaction is reversed relative to the natural host enzyme/natural substrate ion pair interaction. The first component is substantially non-immunogenic in the host and the prodrug second component is not significantly convertible into antineoplastic drug in the host by natural unmutated host enzyme.Type: GrantFiled: June 23, 1997Date of Patent: November 16, 1999Assignee: Zeneca LimitedInventors: Christopher John Taylorson, Hendrikus Johannes Eggelte, Antonio Tarragona-Fiol, Brian Robert Rabin, Francis Thomas Boyle, John Frederick Hennam, David Charles Blakey, Peter Robert Marsham, David William Heaton, David Huw Davies, Anthony Michael Slater, Laurent Francois Andre Hennequin
-
Patent number: 5981234Abstract: Antibiotic 10381a.sub.1, wherein R is hydrogen, is a cytosine-containing antibiotic producible by culturing the novel microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. Derivatives wherein R is a C.sub.1 to C.sub.3 alkyl ester of antibiotic 10381a.sub.1, are also disclosed along with the pharmaceutically acceptable salts of both the native and esterified forms. Antibiotic 10381a.sub.1 inhibits the growth of selected species of yeast, fungi and bacteria. This invention also relates to a novel process for the preparation of the antibiotics 10381b and to a method of using antibiotics 10381b to promote growth in meat-producing animals. These antibiotics are also obtained by the fermentation of a nutrient medium with the novel microorganism Streptomyces arginensis and are active against selected species of bacteria.Type: GrantFiled: June 5, 1995Date of Patent: November 9, 1999Assignee: Pharmacia & Upjohn CompanyInventors: Alexander D. Argoudelis, deceased, Franklin B. Shilliday, Alice L. Laborde, Scott E. Truesdell, Oldrich K. Sebek
-
Patent number: 5948405Abstract: Fucans with low molecular weight having anticoagulant, antithrombinic and antithrombotic activity.Fucan sulfates having molecular weight between 14000 and 29000 Dalton show a remarkable anticoagulant activity both in the global coagulation mechanism (APTT) and in the last phase of coagulation (antithrombinic activity). These compounds are useful also as antithrombotic drugs.Type: GrantFiled: December 18, 1997Date of Patent: September 7, 1999Assignee: Crinos Industria Farmacobiologica S.p.A.Inventors: Armando Cedro, Roberto Porta, Franco Cattaneo, Fabio Trento, Laura Ferro, Ennio Lanzarotti
-
Patent number: 5902583Abstract: The present invention provides a method to achieve radioisotopic localization at tumor sites, i.e., a method of enhancing radiolabeled ligand localization to a tumor in an individual in need of such treatment, comprising the steps of: transducing the tumor with a gene encoding a membrane expressed protein unique to the tumor; and administering to said individual a radiolabeled ligand which specifically binds to the protein. The use of gene therapy technology to induce expression of high affinity membrane molecules/receptors can enhance the specificity of radioisotope localization while the use of radioactive isotopes with the ability to deliver radiation damage across several cell diameters will compensate for less than perfect transduction efficiency.Type: GrantFiled: February 11, 1997Date of Patent: May 11, 1999Assignee: UAB Research FoundationInventors: Donald J. Buchsbaum, David T. Curiel, Mohammad B. Khazaell, David Raben, Murray Stackhouse
-
Patent number: 5877147Abstract: Muramyl peptide compounds are useful in the prophylaxis of cancers and particularly in the treatment of precancerous lesions associated with cancers of the mucosa or epithelium.Type: GrantFiled: July 29, 1996Date of Patent: March 2, 1999Assignee: Peptech (UK) LimitedInventor: Boris Vladimirovich Pinegin
-
Patent number: 5843890Abstract: The present invention is directed to new antibiotic substances denominated antibiotic GE 2270 factors B.sub.1, B.sub.2, C.sub.1, C.sub.2, D.sub.1, D.sub.2, E and T, the addition salts thereof, the pharmaceutical compositions thereof and their use as medicaments, particularly in the treatment of infectious diseases involving microorganisms susceptible to them and their use as animal growth promoters.Type: GrantFiled: June 5, 1995Date of Patent: December 1, 1998Assignee: Gruppo Lepetit S.p.A.Inventors: Enrico Selva, Paolo Tavecchia, Ermenegildo Restelli, Pietro Ferrari, Maurizio Denaro
-
Patent number: 5814295Abstract: The present invention is directed to a method for reliably determining lymph nodes enriched in tumor reactive cells, e.g., CD4+tumor-specific lymphocytes. This method includes the steps of administering to a patient an effective amount of a radiolabeled locator which specifically binds a marker produced by or associated with neoplastic tissue. Time is permitted to elapse following the administration for the radiolabeled locator to preferentially concentrate in any neoplastic tissue and for unbound radiolabeled locator to be cleared, so as to increase the ratio of photon emissions from neoplastic tissue to background photon emissions in the patient. After the time has elapsed, the patient is accessed with a radiation detection probe for determining lymph node sites exhibiting accretion of the radiolabeled locator by detecting with the probe elevated levels of radiation at the lymph node sites.Type: GrantFiled: July 13, 1994Date of Patent: September 29, 1998Assignee: The Ohio State University Research FoundationInventors: Edward W. Martin, Jr., Brian J. Czerniecki, Pierre L. Triozzi, Julian A. Kim
-
Patent number: 5807840Abstract: The present invention discloses a method for treating patients having the CDV associated symptoms or animals carrying or infected by the canine distemper virus (CDV) or having antibodies against the CDV using Product R, a peptide-nucleic acid preparation.Type: GrantFiled: November 4, 1997Date of Patent: September 15, 1998Assignee: Advanced Viral Research Corp.Inventor: Shalom Z. Hirschman
-
Patent number: 5804186Abstract: A nerve cell differentiation promoter which comprises a physiologically active substance NK175203 or a pharmacologically acceptable salt thereof as an active ingredient is provided. It is expected that the nerve cell differentiation promoter of the present invention is applicable to a medicine for dementia, a nerve cell protective medicine or a medicine for peripheral neuropathy caused by anticancer agents.Type: GrantFiled: November 13, 1996Date of Patent: September 8, 1998Assignee: Nippon Kayaku Kabushiki KaishaInventors: Daisuke Komagata, Tomio Morino
-
Patent number: 5785949Abstract: A drink adapted to be consumed by a patient to enable measurement of gastric emptying of the liquid phase, is a fruit juice having mixed and suspended therein a quantity of Spirulina platensis alga grown in a .sup.13 CO.sub.2 atmosphere. These single cell organisms pass from the stomach into the small intestine where they are digested, absorbed and oxidized to produce a detectible rise in the level of .sup.13 CO.sub.2 in the patient's breath which is sampled and the measured valves plotted to enable determination of gastric emptying rate abnormalities.Type: GrantFiled: September 5, 1996Date of Patent: July 28, 1998Assignee: Meretek DiagnosticsInventor: Peter D. Klein
-
Patent number: 5736510Abstract: Antibiotics 10381v, w, x, y, z1, z2, pre-b and t are antibiotics producible by culturing the microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. The structure of Antibiotic 10381y is given below as formula IV. These antibiotics inhibit the growth of selected species of bacteria and may also be useful as a growth promotant in animals.Type: GrantFiled: March 7, 1996Date of Patent: April 7, 1998Assignee: Pharmacia & Upjohn CompanyInventors: Charles Peter Cornell, Stephen Howard Grode, Heinz F. Meyer
-
Patent number: 5707602Abstract: A biscuit adapted to be ingested by a patient to enable measurement of gastric emptying has added prior to baking Spirulina Platensis alga grown in a .sup.13 CO.sub.2 atmosphere. These single cell organisms are oxidized after digestion in the small intestine to produce a detectible rise in level of .sup.13 CO.sub.2 in the patient's breath which is sampled and plotted to enable diagnosis of abnormal gastric emptying rates.Type: GrantFiled: March 25, 1996Date of Patent: January 13, 1998Assignee: Meretek DiagnosticsInventor: Peter D. Klein
-
Patent number: 5695984Abstract: Antibiotic 10381a.sub.1, wherein R is hydrogen, is a cytosine-containing antibiotic producible by culturing the novel microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. Derivatives wherein R is a C.sub.1 to C.sub.3 alkyl ester of antibiotic 10381a.sub.1, are also disclosed along with the pharmaceutically acceptable salts of both the native and esterified forms. Antibiotic 10381a.sub.1 inhibits the growth of selected species of yeast, fungi and bacteria. This invention also relates to a novel process for the preparation of the antibiotics 10381b and to a method of using antibiotics 10381b to promote growth in meat-producing animals. These antibiotics are also obtained by the fermentation of a nutrient medium with the novel microorganism Streptomyces arginensis and are active against selected species of bacteria.Type: GrantFiled: June 5, 1995Date of Patent: December 9, 1997Assignee: Pharmacia & Upjohn CompanyInventors: Alexander D. Argoudelis, deceased, Franklin B. Shilliday, Alice L. Laborde, Scott E. Truesdell, Oldrich K. Sebek
-
Patent number: 5690903Abstract: Methods for the preparation and use of a biological delivery system are disclosed. The method of preparation includes the loading of a non-biological material into a biostructure having a load-bearing structure. The method also includes the removal of some of the biostructure's contents and the loading of a non-biological material into the biostructure. The biostructure is biologically compatible with the host, and preferably is derived from the host, the host's species or a related species. The loaded biostructure is used directly, or it can be targeted to specific cells, tissues and/or organs within a host. The targeted biostructure can be used to deliver the non-biological material to a specified tissue, organ or cell within a host for diagnostic, therapeutic or other purposes.Type: GrantFiled: May 30, 1995Date of Patent: November 25, 1997Inventor: James F. Hainfeld
-
Patent number: 5665328Abstract: Compounds, compositions, their methods of preparation and use in binding bio-affecting substances to the surface membrane of bioparticles, such as enkaryotic cells, without producing appreciable detrimental effect on morphology or physiological function of cells.Type: GrantFiled: December 1, 1992Date of Patent: September 9, 1997Assignee: Phanos Technologies, Inc.Inventors: Paul Karl Horan, Sue Ellen Slezak, Bruce D. Jensen
-
Patent number: 5635207Abstract: In accordance with the present invention, there are provided compositions useful for the in vivo delivery of a biologic, wherein the biologic is associated with a polymeric shell formulated from a biocompatible material. The biologic can be associated with the polymeric shell itself, and/or the biologic, optionally suspended/dispersed in a biocompatible dispersing agent, can be encased by the polymeric shell. In another aspect, the biologic associated with polymeric shell is administered to a subject, optionally dispersed in a suitable biocompatible liquid.Type: GrantFiled: June 7, 1995Date of Patent: June 3, 1997Assignee: Vivorx Pharmaceuticals, Inc.Inventors: Mark W. Grinstaff, Patrick Soon-Shiong, Michael Wong, Paul A. Sandford, Kenneth S. Suslick, Neil P. Desai
-
Patent number: 5567676Abstract: The present invention concerns new antiobiotic substances demoninated de-acyl antibiotics A40926, de-acyl antibiotic A 40926P and antibiotic A 40926 amino glucronyl aglycon, and the use of these substances in the treatment of infectious diseases involving microorganisms susceptible to it.Type: GrantFiled: June 1, 1995Date of Patent: October 22, 1996Assignee: Gruppo Lepetit S.p.AInventors: Enrico Selva, Grazia Beretta, Angelo Borghi, Maurizio Denaro
-
Patent number: 5514649Abstract: The present invention is directed to a new antibiotic substance denominated antibiotic GE 2270 factor C.sub.2a, the addition salts thereof, the pharmaceutical compositions thereof and its use as medicament, particularly in the treatment of infectious diseases involving microorganisms susceptible to it and its use as animal growth promoter.Type: GrantFiled: April 21, 1995Date of Patent: May 7, 1996Assignee: Gruppo Lepetit S.p.A.Inventors: Enrico Selva, Sergio Stella, Luigi Colombo, Maurizio Denaro
-
Patent number: 5505944Abstract: Physiologically active substance NK175203 is produced by culturing bacteria belonging to the genus Streptomyces and capable of producing the physiologically active substance NK175203, and collecting the produced and accumulated substance. The physiologically active substance NK175203 is useful as an effective ingredient of a pharmaceutical composition for promoting proliferation of bone marrow cells.Type: GrantFiled: February 28, 1995Date of Patent: April 9, 1996Assignee: Nippon Kayaku Kabushiki KaishaInventors: Tomio Morino, Ayako Nakatani, Masayuki Kitagawa, Masaya Sato, Takashi Harada, Seiichi Saito
-
Patent number: 5443813Abstract: Methods for the preparation and use of a biological delivery system are disclosed. The method of preparation includes the loading of a non-biological material into a biostructure having a load-bearing structure. The method also includes the removal of some of the biostructure's contents and the loading of a non-biological material into the biostructure. The biostructure is biologically compatible with the host, and preferably is derived from the host, the host's species or a related species. The loaded biostructure is used directly, or it can be targeted to specific cells, tissues and/or organs within a host. The targeted biostructure can be used to deliver the non-biological material to a specified tissue, organ or cell within a host for diagnostic, therapeutic or other purposes.Type: GrantFiled: June 6, 1991Date of Patent: August 22, 1995Assignee: Associated Universities, Inc.Inventor: James F. Hainfeld
-
Patent number: 5420136Abstract: A class of predominantly hydrophobic non-azo N-substituted 1,8-naphthalimide compounds, each bearing, at its 3-position, a nucleofuge and, at its 4-position, a heteroatomic electron-releasing group. The heteroatomic electron-releasing group is being characterized as having a heteroatom directly linked to the 4-position of the ring, and having at least one hydrogen directly attached to the heteroatom. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species initiate chemical changes in lipid bilayer membranes of viruses and other target cells. These changes can eradicate viruses and other target cells. The activated species can also cause structural changes in lipid and any associated proteins and polypeptides at a level beneath the surface of the membrane, leading to polymerization and crosslinking.Type: GrantFiled: August 9, 1993Date of Patent: May 30, 1995Assignee: MicroBioMed CorporationInventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
-
Patent number: 5401709Abstract: The antibiotic AB-041 is described, obtained by controlled aerobic cultivation of Streptomyces sp. NCIMB 40428 in an aqueous culture medium. The antibiotic AB-041 exhibits biological activity, and in particular herbicidal activity.Type: GrantFiled: December 1, 1992Date of Patent: March 28, 1995Assignee: Ministero dell `Universita` e della Ricerca Scientifica e TecnologicaInventors: Nunzio Andriollo, Alessandro Scacchi, Giorgio E. Borgonovi, Giorgio Cassani, Silvia Spera, Gianfranco Guglielmetti, Giorgio Pirali, Giovanni Confalonieri
-
Patent number: 5364624Abstract: A degenerative disease selected from the group consisting of cystic fibrosis, chronic bronchitis and bronchiectasia is treated by administering to a subject a therapeutically effective amount of WS7622A mono-or disulfate or pharmaceutically acceptable salt thereof.Type: GrantFiled: July 7, 1993Date of Patent: November 15, 1994Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Shigehiro Takase, Hiroshi Hatanaka, Masami Ezaki, Eisaku Tsujii, Masanori Okamoto, Nobuharu Shigematsu, Masakuni Okuhara
-
Patent number: 5306496Abstract: Novel antibiotics NK374186A, NK374186B, NK374186B3 and NK374186C3 having antibacterial, antineoplastic, immunomodulation, and liver regeneration promoting activities are provided.NK374186A, NK374186B, NK374186B3 and NK374186C3 are obtained by culturing NK374186 strain (FERM P-12285) (FERM-BP 3870) belonging to the genus Penicillium. NK374186A is a compound represented by a rational formula of C.sub.34 H.sub.61 N.sub.3 O.sub.12 S.sub.9 and having a molecular weight of M+ 735 (FD-MS m/z); NK374186B is a compound represented by a rational formula of C.sub.34 H.sub.61 N.sub.3 O.sub.9 and having a molecular weight of M+ 655 (FD-MS m/z); NK374186B3 is a compound represented by a rational formula of C.sub.34 H.sub.61 N.sub.3 O.sub.9 and having a molecular weight of M+ 655 (FD-MS m/z); and NK374186C3 is a compound represented by a rational formula of C.sub.32 H.sub.59 N.sub.3 O.sub.7 and having a molecular weight of M+ 597 (FD-MS m/z).Type: GrantFiled: June 10, 1992Date of Patent: April 26, 1994Assignee: Nippon Kayaku Kabushiki KaishaInventors: Tomio Morino, Masakazu Nishimoto, Mituyuki Nishide, Akira Masuda, Masatoshi Yamada, Eiji Kawano, Takaaki Nishikiori, Seiichi Saito
-
Patent number: 5292524Abstract: The invention provides loaded platelets that include an absorbed loading vehicle having associated diagnostic or therapeutic agents. A method of loading platelets with diagnostic or therapeutic agents is provided. The method includes combining a loading vehicle having associated diagnostics or therapeutic agents with platelets at sufficient concentration and temperature to allow uptake of the loading vehicle by the platelets. Also provided is a method of targeting diagnostic or therapeutic agents to platelet localizing areas. The method includes the steps of: (a) combining a loading vehicle having associated diagnostic or therapeutic agents with platelets at sufficient concentration and temperature to allow uptake of the loading vehicle by the platelets; (b) isolating the platelets from excess loading vehicle; and (c) administering the isolated platelets to an animal in an effective concentration so as to promote targeting of the isolated platelets to platelet localizing areas.Type: GrantFiled: September 6, 1991Date of Patent: March 8, 1994Assignee: California Institute of TechnologyInventors: Roxanne Male, Wilton E. Vannier
-
Patent number: 5292510Abstract: WS7622A mono- or di-sulfate and pharmaceutically acceptable salts thereof. WS7622A exhibits human leukocyte elastase-inhibiting activity.Type: GrantFiled: June 11, 1991Date of Patent: March 8, 1994Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Shigehiro Takase, Hiroshi Hatanaka, Masami Ezaki, Eisaku Tsujii, Masanori Okamoto, Nobuharu Shigematsu, Masakuni Okuhara
-
Patent number: 5279826Abstract: A method for therapy of disseminated intravascular coagulation, or chronic respiratory tract infectious disease characterized by administering to a patient in need thereof an effective dose suitable for therapeutic treatment of said condition of WS7622A mono- or di-sulfate ester or their pharmaceutically acceptable salt.Type: GrantFiled: June 17, 1992Date of Patent: January 18, 1994Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Noriaki Inamura, Yasuhiko Shinguh, Kunio Nakahara, Yoshitada Notsu, Masanori Okamoto, Shigehiro Takase, Hiroshi Hatanaka, Masami Ezaki, Eisaku Tsujii, Nobuharu Shigematsu, Masakuni Okuhara
-
Patent number: 5276147Abstract: The subject of the present invention is compounds which correspond to the following general formula: ##STR1## in which R.sub.1 and R.sub.3 independently of one another represent H, an alkyl, alkenyl, cycloalkyl, aryl, arylalkyl or an alkylaryl group, a heterocycle, or groups which are unsubstituted or substituted, in particular by one or more hydroxyl or alkoxy groups or halogen;n represents an integer from 1 to 5;i in each case takes values from 1 to n for the n successive ##STR2## links; R.sub.2, R.sub.4.sup.i and R.sub.5.sup.i independently of one another represent H, an alkyl, alkenyl, aryl, alkoxy, hydroxyalkyl, alkoxyalkyl, amido, acyl or carboxyalkyl group, or a salt, or an alkyl ester of the latter; or R.sub.4.sup.i and R.sub.5.sup.i together form an oxo group ##STR3## R.sub.6 and R.sub.7 represent H, or R.sub.6 and R.sub.7 together form an oxo group ##STR4## x represents a 5- or 6-membered heterocycle which contains at least one nitrogen atom, or, in the event that ##STR5## where R.sub.8 and R.sub.Type: GrantFiled: April 19, 1990Date of Patent: January 4, 1994Assignee: Medgenix Group S.A.Inventors: John R. Thornback, Marcel Deblaton, Gillian F. Morgan
-
Patent number: 5229362Abstract: Newly-discovered antibiotic A10255 factors B, C, E, F, G, H, and J are produced by submerged aerobic fermentation of Streptomyces gardneri NRRL 15537 and NRRL 18260 or an A10255-producing variant or mutant thereof. The antibiotics are active against a wide variety of pathogenic bacteria, and also enhance feed-utilization efficiency in chickens, weanling pigs, cattle and sheep. The antibiotics can also be used to detect the thiostrepton-resistance gene in Streptomyces species.Type: GrantFiled: July 17, 1991Date of Patent: July 20, 1993Assignee: Eli Lilly and CompanyInventors: Herbert A. Kirst, Karl H. Michel
-
Patent number: 5139778Abstract: The present invention is directed to new antibiotic substances denominated antibiotic GE 2270 factors A.sub.1, A.sub.2, A.sub.3 and H, the additional salts thereof, the pharmaceutical compositions thereof and their use as medicaments, particularly in the treatment of infectious diseases involving microorganisms susceptible to them.Type: GrantFiled: July 2, 1990Date of Patent: August 18, 1992Assignee: Gruppo Lepetit SpAInventors: Enrico Selva, Paolo Tavecchia
-
Patent number: 5124150Abstract: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.Type: GrantFiled: March 11, 1991Date of Patent: June 23, 1992Assignee: Bristol-Myers Squibb Co.Inventors: Masataka Konishi, Mitsuaki Tsunakawa, Osamu Tenmyo, Takeo Miyaki, Toshikazu Oki
-
Patent number: 5098708Abstract: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.Type: GrantFiled: July 6, 1990Date of Patent: March 24, 1992Assignee: Bristol-Myers Squibb CompanyInventors: Masataka Konishi, Mitsuaki Tsunakawa, Osamu Tenmyo, Takeo Miyaki, Toshikazu Oki
-
Patent number: 5037651Abstract: Dihydro derivatives of LL-E33288, BBM-1075 FR-900405, FR-900406, PD 114759, PD 115028, CL-1577A, CL-1577B, CL-1577D, CL-1577E and CL-1724 antibiotics/antitumor agents are disclosed and described, including the degradation product of LL-E33288 antibiotics/antitumor agents dihydro-LL-E33288-pseudoaglycone.Type: GrantFiled: January 30, 1987Date of Patent: August 6, 1991Assignee: American Cyanamid CompanyInventor: May D. Lee
-
Patent number: 5013550Abstract: Novel compounds, called chloropolysporins B and C, and salts thereof have antibiotic properties and would appear to be members of the class of glycopeptide antibiotics containing chlorine. They may be produced by cultivating a suitable strain of microorganism of the genus Micropolyspora, especially Micropolyspora sp. SANK 60983 (FERM BP-538). They may be combined with conventional pharmaceutically acceptable carriers or diluents for therapeutic use or incorporated into edible excipients, such as feed or water, for use as a growth-promoting agent, especially for farm animals.Type: GrantFiled: February 6, 1990Date of Patent: May 7, 1991Assignee: Sankyo Company LimitedInventors: Tatsuo Haneishi, Takao Okazaki, Akio Torikata, Mutsuo Nakajima
-
Patent number: 4999196Abstract: A novel compound, DC-107, is produced by culturing a microorganism belonging to the genus Streptomyces. It is useful as a medicine because of its antibacterial and anti-tumor activity.Type: GrantFiled: March 29, 1989Date of Patent: March 12, 1991Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Hirofumi Nakano, Mitsunobu Hara, Isami Takahashi, Kozo Asano, Takao Iida, Makoto Morimoto
-
Patent number: 4950477Abstract: This invention concerns a method of preventing a pulmonary infection by a fungus in a subject susceptible to infection by the fungus comprising administering to the subject an amount per dose in an aerosol spray of a polyene or a pharmaceutically acceptable derivative thereof, effective to prevent pulmonary infection by the fungus. This invention further discloses a method of treating pulmonary aspergillosis in a subject comprising administering to the subject an amount per dose in an aerosol spray of a polyene, e.g., amphotericin B or pimaricin, or a pharmaceutically acceptable derivative thereof effective to treat aspergillosis.Type: GrantFiled: August 23, 1988Date of Patent: August 21, 1990Assignee: Memorial Hospital For Cancer and Allied DieseasInventors: Heinz J. Schmitt, Donald Armstrong, Edward M. Bernard
-
Patent number: 4921700Abstract: There is provided new antitumor antibiotic substances designated herein as BBM-1675C and BBM-1675D, said substances being produced by selective chemical hydrolysis of the bioactive components BBM-1675A.sub.1 (esperamicin A.sub.1) or BBM-1675A.sub.2 (esperamicin A.sub.2). The new antitumor antibiotics exhibit both antimicrobial activity and antitumor activity.Type: GrantFiled: May 28, 1987Date of Patent: May 1, 1990Assignee: Bristol-Myers CompanyInventor: Jerzy Golik
-
Patent number: 4918054Abstract: Novel compounds, called chloropolysporins B and C, and salts thereof have antibiotic properties and would appear to be members of the class of glycopeptide antibiotics containing chlorine. They may be produced by cultivating a suitable strain of miroorganism of the genus Micropolyspora, especially Micropolyspora sp. SANK 60983 (FERM BP-538). They may be combined with conventional pharmaceutically acceptable carriers or diluents for therapeutic use or incorporated into edible excipients, such as feed or water, for use as a growth-promoting agent, especially for farm animals.Type: GrantFiled: July 11, 1989Date of Patent: April 17, 1990Assignee: Sankyo Company LimitedInventors: Tatsuo Haneishi, Takao Okazaki, Akio Torikata, Mutsuo Nakajima, Ryuzo Enokita, Toshiaki Katayama, Seigo Iwado
-
Patent number: 4900815Abstract: A sulfated polysaccharide DS4152 useful as an angiogenesis inhibitor or antitumor agent is provided selectively. As the sodium salt, it has the following physicochemical characteristics. Molecular weight by the gel filtration method: 29,000.+-.3,000. Elemental analysis: C: 24.42-25.76%, H: 3.34-3.98%, N: 0.51-0.89%, S: 10.6-11.7% and P: 0.77-1.06%. Sugar and protein contents: Sugar content (%): 57.+-.3 (by phenol sulfuric acid method; standard: galactose). Protein content (%): 1.+-.0.5 (by the Lowry-Folin's method; standard: bovine serum albumin). Specific rotatory power [.alpha.].sub.D.sup.25 : -37.degree..+-.1.degree. (0.5% aq. solution). Characteristic absorption bands in infrared absorption spectrum: 1240, 840 (shoulder), 810 (cm.sup.-1 ; KBr).Type: GrantFiled: May 20, 1987Date of Patent: February 13, 1990Assignee: Daiichi Seiyaku Co., Ltd.Inventors: Noriko Tanaka, Kazuhiro Inoue, Hiroshi Korenaga, Hidemasa Ogawa